摘要
目的:观察苦参素联合阿德福韦酯治疗对慢性乙肝(CHB)患者补体C3、CRP水平及乙型肝炎病毒(HBV)复制的影响。方法:164例CHB患者按随机数字表法分为观察组84例和对照组80例,两组均给予阿德福韦酯治疗48周,观察组在疗程的前24周联用苦参素。在治疗前、24周和48周分别检测补体C3、CRP及HBV-DNA水平。结果:治疗后24周及48周察组HBV-DNA转阴率均高于对照组(P<0.05);治疗后两组补体C3、CRP水平与治疗前比较均有统计学差异,且观察组补体C3水平高于对照组,CRP水平低于对照组,差异有统计学意义(P<0.05)。结论:苦参素联合阿德福韦酯治疗CHB可显著提高疗效,改善肝脏炎症活动和器官免疫功能。
Objective：To investigate the effects of marine in combination with adefovir dipivoxil on C3,C-reation protein and replication of HBV in patients with chronic hepatitis B（CHB）. Method：164 CHB patients were randomly divided into observation group（84 cases）and the control group（80 cases）. All were given adefovir dipivoxil therapy for 48 weeks,and patients in observation group were combined with matrine at the first 24 weeks. The level of C3,CRP and HBV-DNA were detected before and 24 weeks and 48 weeks after treatment. Result：24 weeks and 48 weeks after treatment,the negative rate of HBV-DNA of observation group was higher than that of control group（P〈0.05）. The C3,CRP levels of the two groups after treatment were significant differences compared with those before treatment,and the C3 level of observation group was higher than that of control group,and the level of CRP was lower than that of control group,the difference was statistically significant（P〈0.05）. Conclusion：Marine combined with adefovir dipivoxil in the treatment of CHB can significantly improve the curative effect,and the hepatic inflammatory activity and organism immune function.
出处
《中国医学创新》
CAS
2014年第7期23-24,共2页
Medical Innovation of China
